HEALIUS LIMITED — Director's Dealing 2024

Aug 5, 2024

ASX Announcement (ASX: HLS)

ASX Limited Market Announcements Office Exchange Centre Level 4, 20 Bridge Street Sydney NSW 2000

==> picture [138 x 28] intentionally omitted <==

ACN 064 530 516 REGISTERED OFFICE: LEVEL 22 161 Castlereagh Street SYDNEY NSW 2000 TEL: +61 2 9432 9400 FAX: +61 2 9432 9447

6 August 2024

Replacement Appendix 3Y

Attached is a replacement Appendix 3Y "Change of Director's Interest Notice" for John Mattick.

We advise as follows:

1. The change that occurred related to the transfer of restricted ordinary shares as a result of a registry change of practice to transfer NED restricted shares to a custodian.

2. The Appendix 3Y contained an arithmetic error which has been corrected in the replacement.

3. The Company believes that its current practices are adequate to ensure compliance with the Listing Rules and continues to review its procedures to ensure that it meets its disclosure obligations.

This announcement has been authorised for release by the Chair.

For further information contact:

Mary Weaver Group Company Secretary 02 9432 9400

For over 30 years Healius has been one of Australia’s leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 10,500 employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners.

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HEALIUS LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Mattick
Date of last notice	17 May 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	As shown
Date of change	14 May 2024
No. of securities held prior to change	1. 35,088 Ordinary Shares J & L Mattick Retirement Fund 2. 19,229 Ordinary Shares John Mattick _ 15,093_Shares are subject to a holding lock as “Restricted Shares” under the NED Share Plan
Class	Ordinary Shares
Number acquired	15,093
Number disposed	15,093
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil - a transfer of NED Restricted Shares to the custodian under the Healius NED Share Plan.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	35,088 Ordinary Shares J & L Mattick Retirement Fund Corrected figure: 4,136 Ordinary Shares John Mattick 15,093 Ordinary Shares. Citicorp Nominees Pty Limited on behalf of CPU Share Plans Pty Ltd for John Mattick as beneficial owner
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Transfer of NED Restricted shares to the custodian under the Healius NED Share Plan.

Part 2 – Change of director’s interests in contracts Not applicable

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where prior written N/A clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided?

Authorised by the Company Secretary.

Mary Weaver Company Secretary Date: 6 August 2024

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011